mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Biotechnology company

About

Home > About

Eleventa is a Russian biotechnology company founded in 2012 to develop and commercialize innovative products for the treatment of asthma and other allergic and inflammatory respiratory diseases.

Leading drug candidate OС000459 is a small molecule compound active and selective antagonist of CRTH2 receptors that play a key role in initiating allergic inflammation. The drug has a significant anti-inflammatory effect and is used for the treatment of moderate to severe asthma and other respiratory allergies.

OC000459 developed in partnership with the biotechnology company Oxagen, Ltd. (UK).

 

© Eleventa, 2012—2020